

May 12, 2017

MilliporeSigma and Stelis Biopharma Open First Joint Bioprocess Scale-up Lab in India

- **Joint lab provides end-to-end solutions from bioprocess development to manufacturing for pre-clinical, clinical and commercial supply**
- **Accelerates product availability for clinical trials with greater reliability, cost effectiveness**
- **Offers seamless, robust transfer of optimized processes from small-scale R&D lab to large-scale commercial manufacturing**

Billerica, Massachusetts, May 12, 2017 – [MilliporeSigma](#) today announced the opening of a new joint Process Scale-Up Lab in Bengaluru, India to provide end-to-end solutions from process development to scale-up manufacturing for pre-clinical, clinical and commercial supply.

“Both MilliporeSigma and Stelis bring technological expertise and an extensive bioprocess development and manufacturing portfolio that will help customers accelerate development of biopharmaceuticals for clinical trials and manufacturing with greater reliability and cost effectiveness,” said Udit Batra, CEO, MilliporeSigma.

The collaboration reinforces MilliporeSigma’s position as the premier supplier of process development and clinical state manufacturing solutions, materials and services needed for biologics production.

“In the biopharma space, where the process is the product, the Process Scale-Up Lab fulfils a critical need by offering clients a reliable process bridge between R&D



News Release

and commercial scales,” said Joe Thomas, CEO of Stelis Biopharma. “The collaboration with MilliporeSigma completes the value proposition for CDMO customers by providing an end-to-end solution from process development and scale-up through to manufacturing for pre-clinical, clinical and commercial supply.”

The lab, located at the Stelis Biopharma R&D Facility in Bengaluru, was built as a centre of excellence for process scale-up and manufacturing services. The collaboration brings together Stelis’ end-to-end capabilities in high-yield bioprocess development from cell line to commercial manufacturing scale and MilliporeSigma’s industry leading technological expertise in bioprocessing.

The lab and a soon-to-be-completed cGMP manufacturing facility will house MilliporeSigma’s portfolio of Mobius® bioprocessing equipment and single-use manufacturing components. MilliporeSigma will provide process know-how and application knowledge to help establish the single-use platform technologies at Stelis as part of the collaboration.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its \$17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the \$125 billion global life science industry.

Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of €15.0 billion in 2016. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.